All In Biotech

Drug Trial Radar · NCT06559176

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Modified Ex Vivo Using Prime Editing (PM359) in Participants With Autosomal Recessive Chronic Granulomatous Disease Due to Mutations in the NCF1 Gene

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

12

Planned (sponsor's estimate)

Start

Oct 17, 2024

Primary completion

Jan 2030

Study completion Feb 2030

Sponsor

Lead sponsor
Prime Medicine, Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, multicenter Phase 1/2 study evaluating the safety and efficacy of gene therapy by transplantation of Prime Edited autologous CD34+ stem cells modified ex vivo (PM359) in participants with autosomal recessive Chronic Granulomatous Disease (CGD) caused by mutations in the NCF1 (Neutrophil Cytosolic Factor 1) gene.

Conditions

  • Chronic Granulomatous Disease
  • Granulomatous Disease, Chronic

Interventions

  • PM359Biological

    Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of administration of PM359, as quantified by frequency of adverse events (AEs) after drug product infusionTime frame: PM359 infusion through Month 12 after PM359 infusion
  2. Percentage of participants with sustained reconstitution of NADPH oxidase activity in neutrophilsTime frame: At Month 6 and Month 12 after PM359 infusion, as compared to baseline

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles Medical Center

    Los Angeles, California

  • NIH Clinical Center

    Bethesda, Maryland

  • The Children's Hospital at Tristar Medical Group/Sarah Cannon Center for Blood Cancers

    Nashville, Tennessee

  • CHU - Sainte Justine Hospital

    Montreal, Quebec, Canada

  • University College of London Hospital

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.